We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Clever Leaves Holdings Inc | NASDAQ:CLVR | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.06 | -3.47% | 1.67 | 1.46 | 1.80 | 1.79 | 1.65 | 1.70 | 64,069 | 01:00:00 |
Having already exported cannabis flower from its Portuguese facilities and understanding its nuances and complexity, Clever Leaves decided to start working on product development and on the regulatory pathways more than six months ago and is now ready to benefit from the regulatory change. The company has been able to successfully produce high THC cannabis flower in the Research and Development phase and expects the first exports before the end of the year. Similarly, after having grown milled flower for extraction for over 4 years, the company is ready to export this product now that the regulation is finalized. The company intends to leverage its European Union Good Manufacturing Practices (EU GMP) and Good Agriculture and Collection Practices (GACP) to facilitate its entrance to global markets.
The company has signed commercial agreements in its target markets and expects to be fulfilling them by end of the year. It also plans to launch Colombian flower in Germany through its wholly owned subsidiary Clever Leaves Germany GmbH that has successfully been commercializing the company’s IQANNA brand.
Andrés Fajardo, CEO of the Company, said that “the company has been preparing for the change in regulation and with the resolution issued by the Colombian government, Clever Leaves expects to supply flower for our target markets in 2022”. He also said that “cannabis flower accounts for over 50% of the medical cannabis market in its target geographies and thus represents a significant growth avenue for Clever Leaves in the near future as it will leverage its cost, scale, quality certifications, commercial relationships, and experience selling and exporting flower.”
Julian Wilches, Chief Regulatory Officer of Clever Leaves, said that “with the issuance of Joint Resolution 539, the government provides the industry with a solid and modern set of rules that increases the competitiveness of Clever Leaves. We have been working on the regulatory and technical readiness for complying with the new Colombian requirements and the local specifications in our target markets in order to supply flower from Colombia in 2022 and begin fulfilling commercial agreements already in place".
About Clever Leaves Holdings Inc.
Clever Leaves is a leading multinational operator and licensed producer of pharmaceutical-grade cannabinoids. Its operations in Colombia and Portugal produce cannabinoid active pharmaceutical ingredients (API) and finished products in flower and extract form to a growing base of B2B customers around the globe. Clever Leaves aims to disrupt the traditional cannabis production industry by leveraging environmentally sustainable, ESG-friendly, industrial-scale and low-cost production methods, with the world’s most stringent pharmaceutical quality certifications. For more information, please visit https://cleverleaves.com/en/home/ and follow Clever Leaves on Twitter and LinkedIn.
Clever Leaves Press Contacts:
Rich DiGregorioKCSA Strategic Communications+1-856-889-7351cleverleaves@kcsa.com
Diana SigüenzaStrategic Communications Director+57-310-236-8830diana.siguenza@cleverleaves.com
Clever Leaves Commercial Inquiries:Andrew MillerVice President Sales - EMEA, North America, and Asia-Pacific+1-416-817-1336andrew.miller@cleverleaves.com
Clever Leaves Investor Inquiries:
Cody Slach and Jackie KeshnerGateway Group, Inc. +1-949-574-3860CLVR@gatewayir.com
1 Year Clever Leaves Chart |
1 Month Clever Leaves Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions